KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Finished Goods (2017 - 2020)

Amneal Pharmaceuticals has reported Finished Goods over the past 4 years, most recently at $222.2 million for Q1 2020.

  • For Q1 2020, Finished Goods changed N/A year-over-year to $222.2 million; the TTM value through Mar 2020 reached $222.2 million, changed N/A, while the annual FY2019 figure was $150.7 million, 31.93% down from the prior year.
  • Finished Goods for Q1 2020 was $222.2 million at Amneal Pharmaceuticals, up from $150.7 million in the prior quarter.
  • Over five years, Finished Goods peaked at $250.6 million in Q2 2018 and troughed at $105.8 million in Q4 2017.
  • A 4-year average of $193.7 million and a median of $208.7 million in 2018 define the central range for Finished Goods.
  • Biggest five-year swings in Finished Goods: soared 109.19% in 2018 and later tumbled 31.93% in 2019.
  • Year by year, Finished Goods stood at $105.8 million in 2017, then skyrocketed by 109.19% to $221.4 million in 2018, then tumbled by 31.93% to $150.7 million in 2019, then soared by 47.4% to $222.2 million in 2020.
  • Business Quant data shows Finished Goods for AMRX at $222.2 million in Q1 2020, $150.7 million in Q4 2019, and $168.2 million in Q3 2019.